635 results on '"Pinkus, Geraldine S."'
Search Results
2. Cutaneous Manifestations of Myeloid Neoplasms Exhibit Broad and Divergent Morphologic and Immunophenotypic Features but Share Ancestral Clonal Mutations With Bone Marrow
3. Initial Diagnosis of Classic Hodgkin Lymphoma With Skin Biopsy: A Rare Case and Review of Diagnostic Considerations
4. Global assessment of IRF8 as a novel cancer biomarker
5. miR-15a/16-1 deletion in activated B cells promotes plasma cell and mature B-cell neoplasms
6. Autopsy findings from patients diagnosed with COVID-19 demonstrate unique morphological patterns in bone marrow and lymph node.
7. Multiparametric in situ imaging of NPM1-mutated acute myeloid leukemia reveals prognostically-relevant features of the marrow microenvironment
8. Detection of the KITD816V mutation in myelodysplastic and/or myeloproliferative neoplasms and acute myeloid leukemia with myelodysplasia-related changes predicts concurrent systemic mastocytosis
9. Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host disease
10. Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells
11. Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity
12. Ribosome Levels Selectively Regulate Translation and Lineage Commitment in Human Hematopoiesis
13. Cutaneous manifestations of myeloid neoplasms exhibit broad and divergent morphologic and immunophenotypic features, but share ancestral clonal mutations with bone marrow
14. Constitutive Ras signaling and Ink4a/Arf inactivation cooperate during the development of B-ALL in mice
15. Autopsy findings from patients diagnosed with COVID-19 demonstrate unique morphological patterns in bone marrow and lymph node
16. Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunities
17. Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease
18. Targetable genetic features of primary testicular and primary central nervous system lymphomas
19. Supplementary Table 1 from Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status
20. Supplementary Table 2 from Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status
21. Supplementary methods from Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status
22. Supplementary Figure 1.Optimization IHC on pilot series of cHL cases. from Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status
23. Data from Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status
24. Supplementary Methods, Table 1 from Programmed Death Ligand 1 Is Expressed by Non–Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells
25. Supplementary Figures 1-3 from Programmed Death Ligand 1 Is Expressed by Non–Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells
26. Expanding the Immunophenotypic Spectrum of Neoplastic and Reactive Plasmacytoid Dendritic Cells
27. NPM1 mutations may be associated with adverse outcome in the setting of myeloid neoplasms with complex karyotype
28. Cardiac megakaryocytes in SARS‐CoV ‐2‐positive autopsies
29. Cyclin D1 Is Expressed in Neoplastic Cells of Langerhans Cell Histiocytosis but Not Reactive Langerhans Cell Proliferations
30. Myeloid sarcoma with NPM1 mutation may be clinically and genetically distinct from AML with NPM1 mutation: a study from the Bone Marrow Pathology Group.
31. Pediatric-type nodal follicular lymphoma: an indolent clonal proliferation in children and adults with high proliferation index and no BCL2 rearrangement
32. A case of peripheral T‐cell lymphoma, NOS, mimicking acute monocytic leukemia
33. MYC Immunohistochemistry to Identify MYC-Driven B-Cell Lymphomas in Clinical Practice
34. Follicular Lymphomas can be Induced to Present Alloantigen Efficiently: A Conceptual Model to Improve Their Tumor Immunogenicity
35. Sequential Cleavage of Proinsulin by Human Pancreatic Kallikrein and a Human Pancreatic Kininase
36. Role of immunohistochemistry and flow cytometry in minimal residual disease detection in NPM1 ‐mutated AML
37. Skeletal Muscle and Peripheral Nerve Histopathology in COVID-19
38. Intravascular cytotoxic T-cell lymphoma: A case report and review of the literature
39. Claudin-4 immunohistochemistry is highly effective in distinguishing adenocarcinoma from malignant mesothelioma in effusion cytology
40. The Differentiation and Stress Response Factor XBP-1 Drives Multiple Myeloma Pathogenesis
41. Monoclonal antibody MOC-31 reactivity as a marker for adenocarcinoma in cytologic preparations
42. Consultants
43. The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans
44. Mantle cell lymphoma arising within primary nodal marginal zone lymphoma: a unique presentation of two uncommon B-cell lymphoproliferative disorders
45. The value of Wilms tumor susceptibility gene 1 in cytologic preparations as a marker for malignant mesothelioma
46. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning
47. MYD88 L265P Somatic Mutation in Waldenströmʼs Macroglobulinemia
48. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter
49. List of Consultants
50. NFκB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.